IP
IMDZ

Intellectus Partners’s Immune Design Corp. IMDZ Stock Holding History

Intellectus Partners’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,000
Closed -$1.74K – 606
2018
Q3 		$3K Hold
1,000
– – ﹤0.01% 552
2018
Q2 		$5K Hold
1,000
– – ﹤0.01% 542
2018
Q1 		$3K Buy
+1,000
New +$3.54K ﹤0.01% 561

Other funds holding IMDZ

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Intellectus Partners's IMDZ Position: Q4 2018 in Review

Intellectus Partners sold out of Immune Design Corp. (IMDZ) in Q4 2018, closing a stake of 1,000 shares — an estimated $1.74K sold.

Intellectus Partners first reported a position in IMDZ in Q1 2018 and held it in 3 quarters. The position peaked at $5K in Q2 2018. 64 funds tracked by Wall St. Rank hold IMDZ as of Q4 2018.

  • Intellectus Partners reported no remaining Immune Design Corp. position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 1,000 Immune Design Corp. shares in Q4 2018, an estimated $1.74K.
  • Intellectus Partners first reported a position in Immune Design Corp. in Q1 2018 and held it in 3 quarters.
  • Intellectus Partners's Immune Design Corp. position peaked at $5K in Q2 2018.
  • 64 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.